Open Access

Exploring novel biomarkers in dilated cardiomyopathy‑induced heart failure by integrated analysis and in vitro experiments

  • Authors:
    • Lei Zhou
    • Fei Peng
    • Juexing Li
    • Hui Gong
  • View Affiliations

  • Published online on: May 16, 2023     https://doi.org/10.3892/etm.2023.12024
  • Article Number: 325
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Despite the availability of several effective and promising treatment methods, heart failure (HF) remains a significant public health concern that requires advanced therapeutic strategies and techniques. Dilated cardiomyopathy (DCM) is a crucial factor that contributes to the development and deterioration of HF. The aim of the present study was to identify novel biomarkers and biological pathways to enhance the diagnosis and treatment of patients with DCM‑induced HF using weighted gene co‑expression network analysis (WGCNA). A total of 24 co‑expressed gene modules connected with DCM‑induced HF were obtained by WGCNA. Among these, the blue module had the highest correlation with DCM‑induced HF (r=0.91; P<0.001) and was enriched in the AGE‑RAGE signaling pathway in diabetic complications, the p53 and MAPK signaling pathway, adrenergic signaling in cardiomyocytes, the Janus kinase‑STAT signaling pathway and cGMP/PKG signaling. Eight key genes, including secreted protein acidic and rich in cysteine‑related modular calcium‑binding protein 2 (SMOC2), serpin family A member 3 (SERPINA3), myosin heavy chain 6 (MYH6), S100 calcium binding protein A9 (S100A9), tubulin α (TUBA)3E, TUBA3D, lymphatic vessel endothelial hyaluronic acid receptor 1 (LYVE1) and phospholipase C ε1 (PLCE1), were selected as the therapeutic targets of DCM‑induced HF based on WGCNA and differentially expressed gene analysis. Immune cell infiltration analysis revealed that the proportion of naive B cells and CD4‑activated memory T cells was markedly upregulated in DCM‑induced HF tissues compared with tissues from healthy controls. Furthermore, reverse transcription‑quantitative PCR in AC16 human cardiomyocyte cells treated with doxorubicin showed that among the eight key genes, only SERPINA3, MYH6, S100A9, LYVE1 and PLCE1 exhibited expression levels identical to those revealed by bioinformatics analysis, suggesting that these genes may be involved in the development of DCM‑induced HF.
View Figures
View References

Related Articles

Journal Cover

July-2023
Volume 26 Issue 1

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou L, Peng F, Li J and Gong H: Exploring novel biomarkers in dilated cardiomyopathy‑induced heart failure by integrated analysis and <em>in vitro</em> experiments. Exp Ther Med 26: 325, 2023.
APA
Zhou, L., Peng, F., Li, J., & Gong, H. (2023). Exploring novel biomarkers in dilated cardiomyopathy‑induced heart failure by integrated analysis and <em>in vitro</em> experiments. Experimental and Therapeutic Medicine, 26, 325. https://doi.org/10.3892/etm.2023.12024
MLA
Zhou, L., Peng, F., Li, J., Gong, H."Exploring novel biomarkers in dilated cardiomyopathy‑induced heart failure by integrated analysis and <em>in vitro</em> experiments". Experimental and Therapeutic Medicine 26.1 (2023): 325.
Chicago
Zhou, L., Peng, F., Li, J., Gong, H."Exploring novel biomarkers in dilated cardiomyopathy‑induced heart failure by integrated analysis and <em>in vitro</em> experiments". Experimental and Therapeutic Medicine 26, no. 1 (2023): 325. https://doi.org/10.3892/etm.2023.12024